<?xml version='1.0' encoding='utf-8'?>
<document id="30533000"><sentence text="Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study."><entity charOffset="36-44" id="DDI-PubMed.30533000.s1.e0" text="mitotane" /><entity charOffset="49-58" id="DDI-PubMed.30533000.s1.e1" text="etoposide" /><pair ddi="false" e1="DDI-PubMed.30533000.s1.e0" e2="DDI-PubMed.30533000.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30533000.s1.e0" e2="DDI-PubMed.30533000.s1.e1" /></sentence><sentence text="Background The combination of mitotane and platinum-etoposide chemotherapy is a front-line treatment in metastatic adrenocortical carcinoma (ACC), although this regimen shows limited efficacy"><entity charOffset="30-38" id="DDI-PubMed.30533000.s2.e0" text="mitotane" /><entity charOffset="43-51" id="DDI-PubMed.30533000.s2.e1" text="platinum" /><entity charOffset="52-61" id="DDI-PubMed.30533000.s2.e2" text="etoposide" /><pair ddi="false" e1="DDI-PubMed.30533000.s2.e0" e2="DDI-PubMed.30533000.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30533000.s2.e0" e2="DDI-PubMed.30533000.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30533000.s2.e0" e2="DDI-PubMed.30533000.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30533000.s2.e1" e2="DDI-PubMed.30533000.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30533000.s2.e1" e2="DDI-PubMed.30533000.s2.e2" /></sentence><sentence text=" Pharmacokinetic drug-drug interaction between mitotane, a strong CYP3A4 inducer, and etoposide, which is a substrate of CYP3A4, may contribute to chemoresistance"><entity charOffset="86-95" id="DDI-PubMed.30533000.s3.e0" text="etoposide" /></sentence><sentence text=" The aim of this pilot study was to assess the pharmacokinetic interaction between mitotane and etoposide in ACC patients"><entity charOffset="96-105" id="DDI-PubMed.30533000.s4.e0" text="etoposide" /></sentence><sentence text=" Methods Five consecutive ACC patients treated with platinum etoposide (120-150 mg/m2 day 1-2-3 at cycle 1), with or without concomitant mitotane, were included"><entity charOffset="52-70" id="DDI-PubMed.30533000.s5.e0" text="platinum etoposide" /><entity charOffset="137-145" id="DDI-PubMed.30533000.s5.e1" text="mitotane" /><pair ddi="false" e1="DDI-PubMed.30533000.s5.e0" e2="DDI-PubMed.30533000.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30533000.s5.e0" e2="DDI-PubMed.30533000.s5.e1" /></sentence><sentence text=" In the absence of limiting toxicity, a dose escalation of etoposide was proposed since cycle 2"><entity charOffset="59-68" id="DDI-PubMed.30533000.s6.e0" text="etoposide" /></sentence><sentence text=" Plasma etoposide concentrations were measured using liquid chromatography at 0, 4 and 24 h after each infusion"><entity charOffset="8-17" id="DDI-PubMed.30533000.s7.e0" text="etoposide" /></sentence><sentence text=" Clearance and area under the curve (AUC) of etoposide were determined at each cycle"><entity charOffset="45-54" id="DDI-PubMed.30533000.s8.e0" text="etoposide" /></sentence><sentence text=" Results Patients received two to six chemotherapy cycles, in association with mitotane (N = 4) or after mitotane discontinuation (N = 1)"><entity charOffset="79-87" id="DDI-PubMed.30533000.s9.e0" text="mitotane" /><entity charOffset="89-90" id="DDI-PubMed.30533000.s9.e1" text="N" /><entity charOffset="105-113" id="DDI-PubMed.30533000.s9.e2" text="mitotane" /><entity charOffset="131-132" id="DDI-PubMed.30533000.s9.e3" text="N" /><pair ddi="false" e1="DDI-PubMed.30533000.s9.e0" e2="DDI-PubMed.30533000.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30533000.s9.e0" e2="DDI-PubMed.30533000.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30533000.s9.e0" e2="DDI-PubMed.30533000.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30533000.s9.e0" e2="DDI-PubMed.30533000.s9.e3" /><pair ddi="false" e1="DDI-PubMed.30533000.s9.e1" e2="DDI-PubMed.30533000.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30533000.s9.e1" e2="DDI-PubMed.30533000.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30533000.s9.e1" e2="DDI-PubMed.30533000.s9.e3" /><pair ddi="false" e1="DDI-PubMed.30533000.s9.e2" e2="DDI-PubMed.30533000.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30533000.s9.e2" e2="DDI-PubMed.30533000.s9.e3" /></sentence><sentence text=" Etoposide clearance was two-fold higher with concomitant mitotane (4"><entity charOffset="1-10" id="DDI-PubMed.30533000.s10.e0" text="Etoposide" /><entity charOffset="58-66" id="DDI-PubMed.30533000.s10.e1" text="mitotane" /><pair ddi="false" e1="DDI-PubMed.30533000.s10.e0" e2="DDI-PubMed.30533000.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30533000.s10.e0" e2="DDI-PubMed.30533000.s10.e1" /></sentence><sentence text="95 L/h) than after mitotane discontinuation (2" /><sentence text="53 L/h, P = 0" /><sentence text="014), and 2" /><sentence text="5-fold higher than that in reference population not treated with mitotane (1"><entity charOffset="65-73" id="DDI-PubMed.30533000.s14.e0" text="mitotane" /></sentence><sentence text="81 L/h)" /><sentence text=" Etoposide dose escalation was performed in four patients under mitotane, resulting in two minor tumor responses and one severe toxicity (febrile aplasia) at dose of 300 mg/m2/day"><entity charOffset="1-10" id="DDI-PubMed.30533000.s16.e0" text="Etoposide" /></sentence><sentence text=" Tumor response was associated with higher etoposide AUC (267"><entity charOffset="43-52" id="DDI-PubMed.30533000.s17.e0" text="etoposide" /></sentence><sentence text="3 vs 188" /><sentence text="8 mg" /><sentence text="h/L, P = 0" /><sentence text="04)" /><sentence text=" Conclusion A drug-drug interaction between mitotane and etoposide may contribute to the low efficacy of platinum-etoposide chemotherapy"><entity charOffset="57-66" id="DDI-PubMed.30533000.s22.e0" text="etoposide" /><entity charOffset="105-113" id="DDI-PubMed.30533000.s22.e1" text="platinum" /><entity charOffset="114-123" id="DDI-PubMed.30533000.s22.e2" text="etoposide" /><pair ddi="false" e1="DDI-PubMed.30533000.s22.e0" e2="DDI-PubMed.30533000.s22.e0" /><pair ddi="false" e1="DDI-PubMed.30533000.s22.e0" e2="DDI-PubMed.30533000.s22.e1" /><pair ddi="false" e1="DDI-PubMed.30533000.s22.e0" e2="DDI-PubMed.30533000.s22.e2" /><pair ddi="false" e1="DDI-PubMed.30533000.s22.e1" e2="DDI-PubMed.30533000.s22.e1" /><pair ddi="false" e1="DDI-PubMed.30533000.s22.e1" e2="DDI-PubMed.30533000.s22.e2" /></sentence><sentence text=" This pilot study suggests further a potential benefit of increasing etoposide dose in ACC patients receiving mitotane"><entity charOffset="69-78" id="DDI-PubMed.30533000.s23.e0" text="etoposide" /><entity charOffset="110-118" id="DDI-PubMed.30533000.s23.e1" text="mitotane" /><pair ddi="false" e1="DDI-PubMed.30533000.s23.e0" e2="DDI-PubMed.30533000.s23.e0" /><pair ddi="false" e1="DDI-PubMed.30533000.s23.e0" e2="DDI-PubMed.30533000.s23.e1" /></sentence><sentence text="" /></document>